Metastatic Prostate Cancer research hub
10 indexed studies · 5 currently recruiting
- active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This study looks at a new combination of drugs, cabozantinib and atezolizumab, for men with prostate cancer that has spread and is no longer responding to hormone therapy. It compares this new combination with standard hormone treatments to see if it works better.
United States · Argentina · Australia - recruitingPHASE2
Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)
This study looks at treating prostate cancer that has come back in a few spots. We're comparing targeted radiation or surgery with adding a hormone-blocking drug called ELIGARD® to see if it stops the cancer from growing for longer.
Canada - active not recruitingPHASE2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
This study looks at combining a drug called relugolix with usual radiation therapy for advanced prostate cancer that has spread to limited other areas. It aims to see if this combination helps stop the cancer from spreading further compared to radiation alone.
United States · Canada - active not recruitingPHASE3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
This study looks at new ways to treat prostate cancer that hasn't spread but is at medium risk of doing so. It uses a gene test to decide if less or more intense treatment might be better, hoping to reduce side effects or improve outcomes.
United States · Canada - active not recruitingNA
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
This study compares two treatments for prostate cancer: standard surgery (radical prostatectomy) and a new, less invasive treatment called the TULSA procedure. It aims to see if TULSA is as good at treating cancer but causes fewer side effects, like problems with bladder control or sexual function.
United States · Canada · Finland - active not recruitingPHASE2
Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy
This study is looking at better ways to find and understand prostate cancer before surgery. It uses special scans called Sodium MRI, PSMA PET, and Multiparametric MRI to find cancer more accurately and predict how aggressive it is.
Canada - recruitingPHASE3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
This study compares two ways to give radiation therapy for high-risk prostate cancer. One uses fewer, stronger treatments (SBRT), and the other is the usual longer course. We want to see if the shorter treatment works just as well to stop the cancer from coming back.
United States · Canada · Hong Kong - recruitingPHASE2
INSPIRE: INnovative SABR for Prostate Cancer All IREland
This study is looking at a new, advanced type of radiation treatment for prostate cancer. It aims to reduce side effects while effectively treating the cancer for men with low, intermediate, or some high-risk prostate cancer.
Ireland · United Kingdom - not yet recruitingNA
Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer
This study compares side effects of two radiation treatments for early prostate cancer: radioactive seed implants and external beam radiation. It aims to see if effects like bladder or bowel changes differ, helping doctors choose the best option for you.
United Kingdom - recruitingNA
Dose De-escalation in Prostate Radiotherapy Using the MRL
This study looks at a new way to give radiotherapy for intermediate-risk prostate cancer using a special MRI-guided machine. It aims to see if this treatment can be given safely in fewer sessions, with fewer side effects to the bowel and bladder.
United Kingdom